FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous CAR T-cell immunotherapies

FDA launches Rare Disease Framework Initiative for drug development

FDA announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.

October 16, 2026

Vol.52 No.38

Cancer Policy

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

FDA is requesting nominations by Dec. 14 for voting members to serve on the Tobacco Products Scientific Advisory Committee.

October 16, 2026

Vol.52 No.38

Clinical Roundup

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Two studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide insight into how the immune system can successfully be activated against glioblastoma while revealing why these therapies have historically fallen short.

October 16, 2026

Vol.52 No.38

Clinical Roundup

Wistar Institute study identifies immunotherapy strategy for glioblastoma

Scientists at the Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. The researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and prevented them from coming back.

October 16, 2026

Vol.52 No.38

Drugs & Targets

FDA approves atezolizumab + chemotherapy for stage 3 colon cancer

FDA approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair.

October 16, 2026

Vol.52 No.38

Drugs & Targets

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

FDA expanded the approved indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin to include patients with BCG-unresponsive NMIBC with papillary-only tumors.

October 16, 2026

Vol.52 No.38

FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous CAR T-cell immunotherapies

YOU MAY BE INTERESTED IN

FDA launches Rare Disease Framework Initiative for drug development

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Wistar Institute study identifies immunotherapy strategy for glioblastoma

FDA approves atezolizumab + chemotherapy for stage 3 colon cancer

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

Renew today!

Subscriber content

Never miss an issue!

Login